Passions

Health, spending time with family, crossfit

Experience

SciTec to Be Acquired by Firefly Aerospace

October 5, 2025

Cooley advised SciTec, a leader in advanced national security technologies, on its definitive agreement to be acquired by Firefly Aerospace for approximately $855 million through a combination of $300 million in cash and $555 million in Firefly shares issued to SciTec owners at a price of $50 per share.

Read more

Related contacts

Andrew Lustig
Partner, Reston
Aaron Binstock
Partner, Washington, DC
Heather Harrington
Special Counsel, Boston
Tessa W Bell
Associate, Colorado
Elise Robinson
Associate, Reston
Emily Gibson
Associate, Colorado
Megan Browdie
Partner, Washington, DC
Madison Jones
Partner, Washington, DC
Eileen Marshall
Partner, Washington, DC
Kristen Mathews
Partner, New York
Carly Mitchell
Partner, Washington, DC
David Walsh
Senior Counsel, Reston
Stacey A. Bradford
Special Counsel, Washington, DC
Justin Kisner
Special Counsel, San Diego
Kimberly Nguyen
Special Counsel, Reston
Henry Wendel
Special Counsel, Washington, DC
Etenish Abebe
Associate, Boston
Joy Chow
Associate, New York
Stefan Cohen
Associate, New York
Vicky Kandabarow
Associate, Washington, DC
Nicollette R. Kirby
Associate, Washington, DC
Eileen Leman
Associate, Los Angeles
Amanda Pacheco
Associate, Palo Alto
Tania Soris
Associate, Washington, DC
Patricia Myers
Paralegal Specialist, Colorado
Jake Ironfield
Transactional Quantitative Analyst, New York

Related Practices & Industries

Mabwell Bioscience Announces Formation of Kalexo Bio With Aditum Bio

September 17, 2025

Cooley advised Mabwell Bioscience, an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain, on its exclusive license agreement with Aditum Bio to launch Kalexo Bio, a new company formed in conjunction with an exclusive global license agreement to develop 2MW7141, a novel dual-target small interfering RNA (siRNA) candidate for lipid management in patients with dyslipidemia and for the prevention of high-risk atherosclerotic cardiovascular disease events.

Read more

Related contacts

Charity Williams
Partner, San Diego
Freddy Yip
Associate, Hong Kong
Ken Rollins
Partner in Charge – San Diego, San Diego
Brett Dovman
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Natasha Leskovsek
Of Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Hengrui Pharma and Braveheart Bio Enter Into Exclusive License Agreement

September 5, 2025

Cooley advised Hengrui Pharma, a global pharmaceutical company, on its exclusive license agreement with Braveheart Bio for HRS-1893, a small-molecule inhibitor of cardiac myosin independently developed by Hengrui Pharma with best-in-class potential.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Freddy Yip
Associate, Hong Kong
Steve Przesmicki
Partner, San Diego
Navya Dasari
Associate, New York
Max Levinbook
Associate, San Diego
Jeffrey J. Tolin
Partner, New York
Amanda Pacheco
Associate, Palo Alto
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Zhijing Yu
Associate, Singapore
Christopher Kimball
Partner, Washington, DC
Robert Eisenbach
Of Counsel, San Francisco
Rachel Thorn
Of counsel, New York
Karen Tsai
Special Counsel, Washington, DC

Related Practices & Industries

Argo Biopharma Announces Multi-Asset License and Option Agreements With Novartis

September 3, 2025

Cooley advised Argo Biopharma, a clinical-stage biotechnology company focused on developing next-generation small interfering RNA (siRNA) therapeutics, on its additional strategic collaboration with Novartis for multiple cardiovascular assets in Argo’s pipeline.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Freddy Yip
Associate, Hong Kong
Yuhan Wu
Associate, Palo Alto
Aaron Pomeroy
Partner, Colorado
Amanda Pacheco
Associate, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
David Burns
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Mari Dugas
Associate, Washington, DC
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Patrick Loofbourrow
Partner, Singapore
Phil Mitchell
Partner, New York
Bin Wang
Special Counsel, Palo Alto

Related Practices & Industries

Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals

September 2, 2025

Cooley advised Enlaza Therapeutics, the first covalent biologics platform company, on its multi-target drug discovery collaboration with Vertex Pharmaceuticals, to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia.

Read more

Related contacts

Charity Williams
Partner, San Diego
Emily Mason
Special Counsel, Santa Monica
Ken Rollins
Partner in Charge – San Diego, San Diego
Dylan Kornbluth
Associate, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Rachel Thorn
Of counsel, New York
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Matthew S. Scarano
Associate, San Diego
Max Levinbook
Associate, San Diego

Related Practices & Industries

View more

Admissions and credentials

California

Memberships and affiliations

American Bar Association - Section of Taxation

Hispanic National Bar Association (HNBA)

State Bar of California, Taxation Section

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.